<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg"/>
                                    
                                    <figcaption>J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026. Credit: Skorzewiak/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Johnson &amp; Johnson (J&amp;J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.</p>



<p>This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to J&amp;J’s oncology portfolio, supporting the development of oral, targeted therapies for several solid tumours, including prostate cancer.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - JNJ-6358 in Lung Adenocarcinoma </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>NPVM: 4D Pharma Plc's MRx-518 </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The acquisition includes HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer. This therapy utilises the RIPTAC platform for precision targeting of cancer cells, aiming to address resistance mechanisms.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Additionally, the deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&amp;J’s pipeline.</p>



<p>The company indicated that this platform could potentially enable the development of additional targeted therapies beyond oncology.</p>



<p>With the deal closing in 2025, J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>The total impact on adjusted earnings per share is expected to be around $0.20, divided equally between 2025 and 2026, reflecting charges related to Halda employee equity, financing, and integration costs.</p>



<p>J&amp;J innovative medicine worldwide chairman and executive vice president Jennifer Taubert said: “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines.</p><div id="slot-two"></div>



<p>“We are excited to formally welcome the talented Halda team to J&amp;J and look forward to working together to achieve our shared goal of eliminating cancer.”</p>



<p>J&amp;J innovative medicine R&amp;D executive vice-president John Reed said: “Now that we have finalised this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”</p>



<p>In November 2025, J&amp;J signed a definitive agreement for the acquisition of Halda.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
Discover the Impact

             </div>

<p>Johnson & Johnson (J&J) has acquired Halda Therapeutics for $3.05 billion in cash, enhancing its oncology portfolio with Halda's Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. This acquisition includes HLD-0915, an oral therapy for prostate cancer, and early-stage candidates for other tumors. J&J expects earnings dilution of approximately $0.20 per share in 2025 and 2026 due to integration costs. J&J's executives emphasize the strategic importance of this acquisition in advancing cancer treatment and developing new therapies.</p>

Johnson & Johnson acquires Halda Therapeutics for $3.05bn